Guest guest Posted December 22, 2010 Report Posted December 22, 2010 J Hepatol. 2010 Dec 5. [Epub ahead of print] Hepatitis B Surface Antigen:Relation to Hepatitis B Replication Parameters in HBeAg-Negative Chronic Hepatitis B. Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T, Karayiannis P. Division of Internal Medicine, Athens University Medical School, Athens, Greece. Abstract BACKGROUND & AIMS: Translation of HBsAg depends on transcription of the appropriate mRNAs from cccDNA, but its relation to other hepatitis B virus (HBV) replication parameters is not known, inasmuch as integrated sequences of HBV-DNA may also contribute to its serum levels, especially in HBeAg-negative chronic hepatitis B (CHB) patients. METHODS: We investigated HBsAg serum levels, its hepatocellular expression and their relationship to HBV replicative- and host-response parameters before treatment in 54 HBeAg-negative CHB patients and in 15 of them after 40.1±33.3 months of virological response on oral antiviral (NUC) therapy also. Liver cccDNA and HBV-DNA quantitation, HBsAg- and HBcAg-immunostaining were performed in the same needle biopsy material, while serum HBsAg and HBV-DNA levels were measured in samples drawn on the day of liver biopsy RESULTS: In untreated patients, serum HBsAg correlated positively with HBsAg-positive hepatocytes/mm(2) (P=0.003) and weakly with serum HBV-DNA, but not with cccDNA, liver HBV-DNA, HBcAg-positive hepatocytes/mm(2) or ALT. cccDNA correlated significantly with liver HBV-DNA (P<0.00001), ALT (P=0.001) and serum HBV-DNA levels (P=0.012) but not with liver HBsAg or HBcAg. Antiviral therapy decreased serum HBsAg levels by 79.6% (P=0.012) and liver HBV-DNA by 84.4% (P=0.026) in paired comparisons and, as expected, significantly decreased serum HBV-DNA and ALT levels, but not cccDNA. CONCLUSIONS: In untreated HBeAg-negative CHB, serum HBsAg levels reflect liver HBsAg, but not cccDNA or liver HBV-DNA, suggesting that they are not solely dependent on the replicative cycle of HBV. Effective NUC therapy for 3.34 years significantly lowers serum HBsAg and liver HBV-DNA, but not cccDNA. European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. PMID: 21145875 [PubMed - as supplied by publisher] Quote
Guest guest Posted December 22, 2010 Report Posted December 22, 2010 J Hepatol. 2010 Dec 5. [Epub ahead of print] Hepatitis B Surface Antigen:Relation to Hepatitis B Replication Parameters in HBeAg-Negative Chronic Hepatitis B. Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T, Karayiannis P. Division of Internal Medicine, Athens University Medical School, Athens, Greece. Abstract BACKGROUND & AIMS: Translation of HBsAg depends on transcription of the appropriate mRNAs from cccDNA, but its relation to other hepatitis B virus (HBV) replication parameters is not known, inasmuch as integrated sequences of HBV-DNA may also contribute to its serum levels, especially in HBeAg-negative chronic hepatitis B (CHB) patients. METHODS: We investigated HBsAg serum levels, its hepatocellular expression and their relationship to HBV replicative- and host-response parameters before treatment in 54 HBeAg-negative CHB patients and in 15 of them after 40.1±33.3 months of virological response on oral antiviral (NUC) therapy also. Liver cccDNA and HBV-DNA quantitation, HBsAg- and HBcAg-immunostaining were performed in the same needle biopsy material, while serum HBsAg and HBV-DNA levels were measured in samples drawn on the day of liver biopsy RESULTS: In untreated patients, serum HBsAg correlated positively with HBsAg-positive hepatocytes/mm(2) (P=0.003) and weakly with serum HBV-DNA, but not with cccDNA, liver HBV-DNA, HBcAg-positive hepatocytes/mm(2) or ALT. cccDNA correlated significantly with liver HBV-DNA (P<0.00001), ALT (P=0.001) and serum HBV-DNA levels (P=0.012) but not with liver HBsAg or HBcAg. Antiviral therapy decreased serum HBsAg levels by 79.6% (P=0.012) and liver HBV-DNA by 84.4% (P=0.026) in paired comparisons and, as expected, significantly decreased serum HBV-DNA and ALT levels, but not cccDNA. CONCLUSIONS: In untreated HBeAg-negative CHB, serum HBsAg levels reflect liver HBsAg, but not cccDNA or liver HBV-DNA, suggesting that they are not solely dependent on the replicative cycle of HBV. Effective NUC therapy for 3.34 years significantly lowers serum HBsAg and liver HBV-DNA, but not cccDNA. European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. PMID: 21145875 [PubMed - as supplied by publisher] Quote
Guest guest Posted December 22, 2010 Report Posted December 22, 2010 J Hepatol. 2010 Dec 5. [Epub ahead of print] Hepatitis B Surface Antigen:Relation to Hepatitis B Replication Parameters in HBeAg-Negative Chronic Hepatitis B. Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T, Karayiannis P. Division of Internal Medicine, Athens University Medical School, Athens, Greece. Abstract BACKGROUND & AIMS: Translation of HBsAg depends on transcription of the appropriate mRNAs from cccDNA, but its relation to other hepatitis B virus (HBV) replication parameters is not known, inasmuch as integrated sequences of HBV-DNA may also contribute to its serum levels, especially in HBeAg-negative chronic hepatitis B (CHB) patients. METHODS: We investigated HBsAg serum levels, its hepatocellular expression and their relationship to HBV replicative- and host-response parameters before treatment in 54 HBeAg-negative CHB patients and in 15 of them after 40.1±33.3 months of virological response on oral antiviral (NUC) therapy also. Liver cccDNA and HBV-DNA quantitation, HBsAg- and HBcAg-immunostaining were performed in the same needle biopsy material, while serum HBsAg and HBV-DNA levels were measured in samples drawn on the day of liver biopsy RESULTS: In untreated patients, serum HBsAg correlated positively with HBsAg-positive hepatocytes/mm(2) (P=0.003) and weakly with serum HBV-DNA, but not with cccDNA, liver HBV-DNA, HBcAg-positive hepatocytes/mm(2) or ALT. cccDNA correlated significantly with liver HBV-DNA (P<0.00001), ALT (P=0.001) and serum HBV-DNA levels (P=0.012) but not with liver HBsAg or HBcAg. Antiviral therapy decreased serum HBsAg levels by 79.6% (P=0.012) and liver HBV-DNA by 84.4% (P=0.026) in paired comparisons and, as expected, significantly decreased serum HBV-DNA and ALT levels, but not cccDNA. CONCLUSIONS: In untreated HBeAg-negative CHB, serum HBsAg levels reflect liver HBsAg, but not cccDNA or liver HBV-DNA, suggesting that they are not solely dependent on the replicative cycle of HBV. Effective NUC therapy for 3.34 years significantly lowers serum HBsAg and liver HBV-DNA, but not cccDNA. European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. PMID: 21145875 [PubMed - as supplied by publisher] Quote
Guest guest Posted December 22, 2010 Report Posted December 22, 2010 J Hepatol. 2010 Dec 5. [Epub ahead of print] Hepatitis B Surface Antigen:Relation to Hepatitis B Replication Parameters in HBeAg-Negative Chronic Hepatitis B. Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T, Karayiannis P. Division of Internal Medicine, Athens University Medical School, Athens, Greece. Abstract BACKGROUND & AIMS: Translation of HBsAg depends on transcription of the appropriate mRNAs from cccDNA, but its relation to other hepatitis B virus (HBV) replication parameters is not known, inasmuch as integrated sequences of HBV-DNA may also contribute to its serum levels, especially in HBeAg-negative chronic hepatitis B (CHB) patients. METHODS: We investigated HBsAg serum levels, its hepatocellular expression and their relationship to HBV replicative- and host-response parameters before treatment in 54 HBeAg-negative CHB patients and in 15 of them after 40.1±33.3 months of virological response on oral antiviral (NUC) therapy also. Liver cccDNA and HBV-DNA quantitation, HBsAg- and HBcAg-immunostaining were performed in the same needle biopsy material, while serum HBsAg and HBV-DNA levels were measured in samples drawn on the day of liver biopsy RESULTS: In untreated patients, serum HBsAg correlated positively with HBsAg-positive hepatocytes/mm(2) (P=0.003) and weakly with serum HBV-DNA, but not with cccDNA, liver HBV-DNA, HBcAg-positive hepatocytes/mm(2) or ALT. cccDNA correlated significantly with liver HBV-DNA (P<0.00001), ALT (P=0.001) and serum HBV-DNA levels (P=0.012) but not with liver HBsAg or HBcAg. Antiviral therapy decreased serum HBsAg levels by 79.6% (P=0.012) and liver HBV-DNA by 84.4% (P=0.026) in paired comparisons and, as expected, significantly decreased serum HBV-DNA and ALT levels, but not cccDNA. CONCLUSIONS: In untreated HBeAg-negative CHB, serum HBsAg levels reflect liver HBsAg, but not cccDNA or liver HBV-DNA, suggesting that they are not solely dependent on the replicative cycle of HBV. Effective NUC therapy for 3.34 years significantly lowers serum HBsAg and liver HBV-DNA, but not cccDNA. European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. PMID: 21145875 [PubMed - as supplied by publisher] Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.